Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.44 |
| ▸ | TET3 | O43151 | 1/20 | 0.43 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.43 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.43 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.43 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.43 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.43 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22027030 | 0.88 | NAAA (0.44) | NAAALMNASMN1; SMN2KMT2ACA1 | |
| SCHEMBL22027277 | 0.84 | DGAT1 (0.46) | NAAALMNASMN1; SMN2KMT2ACA1 | |
| SCHEMBL25387067 | 0.84 | NAAA (0.52) | NAAALMNASMN1; SMN2CA1CA2 | |
| SCHEMBL22027200 | 0.83 | KMT2A (0.45) | NAAALMNASMN1; SMN2KMT2ACA1 | |
| SCHEMBL12936217 | 0.82 | KMT2A (0.66) | LMNASMN1; SMN2KMT2AHSD11B1 | |
| SCHEMBL29598198 | 0.81 | MEN1 (0.49) | NAAALMNASMN1; SMN2KMT2ACA1 | |
| SCHEMBL18043699 | 0.80 | CA1 (0.55) | NAAACA1CA2NPC1MAPT | |
| SCHEMBL29525348 | 0.80 | KMT2A (0.48) | LMNAKMT2ACES2CES1NPC1 | |
| SCHEMBL17582383 | 0.79 | MEN1 (0.49) | LMNASMN1; SMN2KMT2AHSD11B1L3MBTL1 | |
| SCHEMBL22362684 | 0.78 | LMNA (0.48) | NAAALMNASMN1; SMN2KMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114450283-B | 3, 6-Diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their use as pro-apoptotic agents | 法国施维雅药厂 | 2024-05-07 | — | — | CN | disclosed |
| WO-2023152182-A1 | NOVEL COMPOUNDS MODULATING MIR-155 | SAVERNA THERAPEUTICS AG (CH) | 2023-08-17 | — | — | WO | disclosed |
| US-20220289734-A1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | LES LABORATOIRES SERVIER (FR) | 2022-09-15 | — | — | US | disclosed |
| CN-114450283-A | 3, 6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their use as pro-apoptotic agents | 法国施维雅药厂 | 2022-05-06 | — | — | CN | disclosed |
| US-10689357-B2 | N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and use thereof | NORTHEASTERN UNIVERSITY (US) | 2020-06-23 | — | — | US | disclosed |
| US-10689357-B2 | N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and use thereof | NORTHEASTERN UNIVERSITY (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190345132-A1 | N-Acylethanolamine Hydrolyzing Acid Amidase (NAAA) Inhibitors And Use Thereof | NORTHEASTERN UNIVERSITY | 2019-11-14 | — | — | US | disclosed |
| US-20190345132-A1 | N-Acylethanolamine Hydrolyzing Acid Amidase (NAAA) Inhibitors And Use Thereof | NORTHEASTERN UNIVERSITY | 2019-11-14 | — | — | US | disclosed |
| WO-2019217977-A1 | N-ACYLETHANOLAMINE HYDROLYZING ACID AMIDASE (NAAA) INHIBITORS AND USE THEREOF | NORTHEASTERN UNIVERSITY (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689357-B2 | N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and use thereof | NAAA, NAT1, ACHE | NAAA 1/4885LMNA 4540/4885SMN1; SMN2 675/4885 |
| US-20190345132-A1 | N-Acylethanolamine Hydrolyzing Acid Amidase (NAAA) Inhibitors And Use Thereof | NAAA, NAT1, ACHE | NAAA 1/4885LMNA 4540/4885SMN1; SMN2 675/4885 |
| US-20220289734-A1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | CASP3, BAX, CASP2 | NAAA 2699/4885LMNA 117/4885SMN1; SMN2 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.